Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

antagonist

antagonist is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 8
News articles 0
Drug details — antagonist
Class
—
Route
—
Patents
20
Programs
8
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

antagonist is an FDA-listed pharmaceutical active ingredient.

Key facts

INN antagonist

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. IM027068 Phase 3 · Bristol-Myers Squibb Australia · Idiopathic pulmonary fibrosis
  2. IM0271015 Phase 3 · Bristol-Myers Squibb Australia · Progressive Pulmonary Fibrosis
  3. UC-0107/1718 Phase 3 · Ningbo Cancer Hospital · Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for tr
  4. 2022/3418 INDIGO Phase 2 · George Institute for · Adult patients with a histologically confirmed TLS-positive
  5. DRI17476 Phase 2 · Sanofi-Aventis U.S · Type 1 diabetes mellitus
  6. alpha receptor antagonist Phase 1 · Chinese Academy of · Prostatic Hypertrophy, Benign
  7. CAPA001 Approved · Chinese Academy of · Atrial Fibrillation
  8. P2Y12 antagonist monotherapy Unknown · Vera Therapeutics · Coronary Artery Disease

Related patents

Browse patents

  1. WO 2026106499

    ANTAGONISTES DU RÉCEPTEUR DE L'ORÉXINE : COMPOSÉS 2-AZABICYCLIQUES

    Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2026062071

    ANTAGONISTES DE TNFR1 ET AGONISTES DE TNFR2 POUR LE TRAITEMENT DE LA DOULEUR AIGUË

    Expires Wed Mar 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2026013287

    DÉRIVÉS DE QUINAZOLINE UTILISÉS EN TANT QU'ANTAGONISTES DE GIPR

    Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2025259831

    FORMES CRISTALLINES D'UN ANTAGONISTE DE LPA1

    Expires Wed Dec 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. WO 2025247801

    DÉTERMINATION D'UN DOSAGE D'UN ANTAGONISTE DU RÉCEPTEUR MINÉRALOCORTICOÏDE NON STÉROÏDIEN

    Expires Wed Nov 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12421517

    Genetic modification of mammalian cells to confer resistance to CSF1R antagonists

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12396988

    Methods of using muscarinic antagonists in the treatment of depression

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12398212

    Methods for treating or preventing asthma by administering an IL-4R antagonist

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12390462

    Muscarinic acetylcholine M1 receptor antagonists

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12383536

    CRF receptor antagonists and methods of use

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12377135

    GHRH antagonists for use in a method of treating sarcoidosis

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 2025195525

    ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OF SYSTEMIC DISEASES IN CATS

    Expires Wed Jun 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12331099

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12286483

    Method of treating cancer using CD137 antibodies and PD-1 antagonists

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12280046

    Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12280093

    Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12281078

    Quinoline cGAS antagonist compounds

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12258316

    Biphenyl compounds useful as muscarinic receptor antagonists

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12252488

    HPK1 antagonists and uses thereof

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12226417

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is antagonist?

antagonist is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.